Administrative Processing of Submissions and Applications: Human or Disinfectant Drugs

Administrative Processing of Submissions and Applications: Human or Disinfectant Drugs

Published on April 18, 2018

Author: Bhavesh Patel, C. Chem. 

On March 1, 2018, the guidance document “Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs” (the “Guidance Document”) came into effect. The Guidance Document applies to drug submissions and applications involving biologics, radiopharmaceuticals, human pharmaceuticals and disinfectants regulated under the Food and Drugs Act. The coming into effect of the Guidance Document will be April 1, 2019 in respect of disinfectant drugs.

The Guidance Document describes when to file drug submissions and applications for administrative processing and also describes the roles and responsibilities of manufacturers. The Guidance Document also explains various document requirements and submission/application types, drug identification number issuance and notifications, labelling and fees. Of note, contact lens disinfectants have been removed from the document. 

Please see the below link for access to the Guidance Document.

Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media. 

Reference:

https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/guidance-administrative-processing-human-disinfectant-drugs/pub1-eng.pdf

Related Articles

Pragmatic Clinical Trials: Testing Treatments in the Real-World

Pragmatic Clinical Trials: Testing Treatments in the Real-World

What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...

The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022

The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022

The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....